Spots Global Cancer Trial Database for Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
Official Title: Neoadjuvant Therapy With FEC Followed by Weekly Paclitaxel and Concurrent Trastuzumab in Her2 Positive Non Operable Breast Cancer. Phase II Study.
Study ID: NCT01340430
Conditions
Interventions
Study Description
Brief Summary: The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2 (HER2) positive non operable breast cancer
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Istituto Nazionale per La Ricerca sul Cancro (IST), Genoa, Ge, Italy
Ospedale S. Maria della Misericordia - Oncologia Medica, Perugia, PG, Italy
Fondazione del Piemonte per l'Oncologia - IRCC di Candiolo, Candiolo, TO, Italy
Ospedale Ostetrico Ginecologico S. Anna Di Torino - Oncologia Medica, Torino, To, Italy
Ospedale Mauriziano Umberto I - Ginecologia Oncologica, Torino, TO, Italy
Ospedale Sacro Cuore - Don Calabria - Oncologia Medica, Negrar, VR, Italy
Contact Details
Name: Lucia Del Mastro, MD
Affiliation: National Institute For Cancer Reasearch
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
